Ozempic Pregnancy Label: US, EU and UK Guidance Compared

If you're thinking about Ozempic pregnancy plans, the Ozempic pregnancy label is the first document to read. It tells you what the manufacturer has reported, what it advises, and how far ahead of trying to conceive you should stop. In this post we'll walk through the US prescribing information, the European and UK summaries of product characteristics, and the questions to bring to your doctor before you change anything.

Why the label is the best starting point

A label is a legal document, and it gets updated over time. An older copy can point you toward advice that has since changed, so check the revision date on any version you read. Write that date down next to the link so you can compare later.

For the US, the Ozempic prescribing information is published by Novo Nordisk. For Europe, the summary of product characteristics (SmPC) is listed on the European Medicines Agency page for Ozempic. For the UK, the electronic Medicines Compendium (eMC) hosts the SmPC used in that market.

Confirm the indication before you compare anything. Ozempic and Wegovy are brand names, and semaglutide is the active ingredient. Indications and doses differ between countries, so a label from one market may not match what you've been prescribed somewhere else.

Keep in mind that labels are written for healthcare professionals. They're dense and full of cross-references, so don't worry if one reads like a manual. Start with the pregnancy section and the patient counseling section.

What the US prescribing information says

Start with section 8.1, Pregnancy. According to the US label, Ozempic should be discontinued at least 2 months before a planned pregnancy. That window is tied to how long semaglutide stays in the body, which we'll get to shortly.

Pay attention to how the label describes the evidence. It reports fetal effects in animal studies and states that human data are limited. Those two points carry most of the weight in the label's advice. If the label gives a specific number, quote it exactly from the document. If it doesn't, don't fill the gap from memory.

Then read the patient counseling section, which turns the clinical language into what you should do and tell your care team. You can find a plain-language walkthrough of these sections in the label-reading guide on OzemNews.

How the EU and UK SmPCs word the advice

In the European SmPC, pregnancy guidance sits in section 4.6, Fertility, pregnancy and lactation. The UK version follows the same SmPC format and covers the same topics. The overall structure is familiar, but the wording isn't copied from the US text, and the details can differ.

Read section 4.6 in each document, sentence by sentence. Look for three things: how long before conception the drug should be stopped, whether the text asks you to use effective contraception, and whether it asks you to keep that method going during treatment. Those are the lines that change what you do.

I haven't listed every wording difference here, because a paraphrase can blur the exact meaning. Quote the sentence you're reading and bring it to your appointment. If you move between countries, check the local document before you assume the advice carried over.

The washout math: why the gap is long

The US label gives semaglutide's half-life as about one week. Half-life is the time it takes for the amount of drug in the body to fall by half. One half-life doesn't clear the drug, though. It takes several half-lives before levels are very low, and that's why the window runs to months rather than days.

The cutoff depends on your last injection, not on the day you decided to start trying. If you stopped two weeks ago, the calendar alone doesn't tell you whether you're past the window. Count from the date of your last dose and ask your prescriber to confirm the exact date that applies to you.

Missed or late doses can change the timeline. If you skipped doses, restarted after a break, or moved your injection day, the dates you were given earlier may no longer hold. Talk with your prescriber about your actual dosing history instead of doing the arithmetic alone. This post can't tell you what to do with your dose.

Contraception and oral medicines during treatment

Check whether the label names oral contraceptives specifically. If it doesn't, the general caution about oral medicines still applies. Semaglutide slows gastric emptying, which can change how quickly and how much of a pill gets absorbed. Look in the drug interactions section for any discussion of oral medicines.

Also check whether the label asks for monitoring after dose changes of oral medicines. If it does, note exactly what it requests. If it stays silent on the point, put the question to your doctor rather than assuming the answer.

Which method suits you is a clinical decision. People often discuss barrier methods, long-acting options such as intrauterine devices, and other choices. Ask which one fits your history and whether it should continue after you stop the drug. For more background on this side of the question, read the contraception and GLP-1 articles on OzemNews.

A pre-conception checklist for the doctor visit

Bring a short list so the appointment stays on track. Start with these three questions:

• What is the safe stop date, based on my last dose?
• Which contraceptive method should I keep using until then?
• How should I track blood sugar and weight during the pause?

If you have type 2 diabetes, stopping semaglutide can change your glucose control, so ask which targets apply before pregnancy. The American Diabetes Association Standards of Care in Diabetes, 2025 edition, published in December 2024 in Diabetes Care, includes a section on managing diabetes in pregnancy. ACOG Practice Bulletin No. 201, Pregestational Diabetes Mellitus, was published in 2018. Check whether a newer version exists before you rely on it.

Pack a simple folder. Include your full medication list with doses, the dates of your last few injections, recent lab results, and any glucose or weight logs you keep. A folder like that helps your doctor work through the plan faster than memory alone.

The decision is individual. Your history, your other conditions, and your timeline all shape the answer, so it belongs in a conversation with your own clinician.

Where the evidence is still thin

Human data on semaglutide in pregnancy are limited, and the labels say so. That limit doesn't prove harm, and it doesn't prove safety. It means the decision needs careful planning and a clear conversation with your doctor.

Not every medical society has published a position on GLP-1 drugs and pregnancy. Before you rely on any guidance, find out what exists, who wrote it, and when. The date tells you whether the advice reflects current evidence.

Careful wording keeps the conversation honest. Phrases like may help or depends on your case describe what we know. Promises don't, because no label offers a guarantee.

Your next steps are straightforward. Read the current label for your country and note its revision date. Book an appointment before you stop anything. Bring your question list and your dosing history. If you'd like a heads-up when labels or guidelines change, the OzemNews team publishes regular summaries of those updates.

FAQ

Should I stop Ozempic before trying to conceive?

The US label advises stopping at least 2 months before a planned pregnancy. Confirm the timing for your case with your prescriber, since the date of your last dose matters.

Does the two-month rule apply the same way to everyone?

The label gives general guidance. Your prescriber decides how it fits your situation, including missed doses and other medicines.

Can I rely on birth control pills while taking Ozempic?

Check whether the label names oral contraceptives. If it doesn't, the general caution about oral medicines applies, so ask your doctor which method suits you.

Where can I find the current label?

Use the Novo Nordisk US prescribing information, the EMA page for Ozempic, and the UK eMC. Always note the revision date on the version you read.

Sources

• Ozempic (semaglutide) prescribing information, Novo Nordisk
• Ozempic, European public assessment report (EPAR), European Medicines Agency
• Electronic Medicines Compendium (eMC), search results for Ozempic, UK
• ADA Standards of Care in Diabetes, 2025, Diabetes Care 48(Supplement 1), published December 2024
• ACOG Practice Bulletin No. 201, Pregestational Diabetes Mellitus, 2018